Cytochrome P450: Implications for human breast cancer (Review)
- Authors:
- Bin Luo
- Dandan Yan
- Honglin Yan
- Jingping Yuan
-
Affiliations: Department of Pathology, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, P.R. China - Published online on: May 24, 2021 https://doi.org/10.3892/ol.2021.12809
- Article Number: 548
-
Copyright: © Luo et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
 |
|
Lakhani SR, Ellis IO, Schnitt SJ, Pan PH and van de Vijver MJ: WHO Classifcation of Tumours of the Breast. WHO Classifcation of Tumours. 4th edition. 4. IARC Press; Lyon: pp. 82–134. 2012 | |
|
Desantis CE, Ma J, Gaudet MM, Newman LA, Miller KD, Goding SA, Jemal A and Siegel RL: Breast cancer statistics, 2019. CA Cancer J Clin. 69:438–451. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Dumitrescu RG and Cotarla I: Understanding breast cancer risk-where do we stand in 2005? J Cell Mol Med. 9:208–221. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Gonzalez FJ and Gelboin HV: Role of human cytochromes P450 in the metabolic activation of chemical carcinogens and toxins. Drug Metab Rev. 26:165–183. 1994. View Article : Google Scholar : PubMed/NCBI | |
|
Ding X and Kaminsky LS: Human extrahepatic cytochromes P450: Function in xenobiotic metabolism and tissue-selective chemical toxicity in the respiratory and gastrointestinal tracts. Annu Rev Pharmacol Toxicol. 43:149–173. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Murray GI: The role of cytochrome P450 in tumour development and progression and its potential in therapy. J Pathol. 192:419–426. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Gajjar K, Martin-Hirsch PL and Martin FL: CYP1B1 and hormone-induced cancer. Cancer Lett. 324:13–30. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Nebert DW and Russell DW: Clinical importance of the cytochromes P450. Lancet. 360:1155–1162. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Luthra A, Denisov IG and Sligar SG: Spectroscopic features of cytochrome P450 reaction intermediates. Arch Biochem Biophys. 507:26–35. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Nelson DR: Cytochrome P450 nomenclature, 2004. Methods Mol Biol. 320:1–10. 2006.PubMed/NCBI | |
|
Pelkonen O, Turpeinen M, Hakkola J, Honkakoski P, Hukkanen J and Raunio H: Inhibition and induction of human cytochrome P450 enzymes: Current status. Arch Toxicol. 82:667–715. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Nelson DR, Zeldin DC, Hoffman SM, Maltais LJ, Wain HM and Nebert DW: Comparison of cytochrome P450 (CYP) genes from the mouse and human genomes, including nomenclature recommendations for genes, pseudogenes and alternative-splice variants. Pharmacogenetics. 14:1–18. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Thelen K and Dressman JB: Cytochrome P450-mediated metabolism in the human gut wall. J Pharm Pharmacol. 61:541–558. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Renaud HJ, Cui JY, Khan M and Klaassen CD: Tissue distribution and gender-divergent expression of 78 cytochrome P450 mRNAs in mice. Toxicol Sci. 124:261–277. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Guengerich FP: Mechanisms of cytochrome P450 substrate oxidation: MiniReview. J Biochem Mol Toxicol. 21:163–168. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Furge LL and Guengerich FP: Cytochrome P450 enzymes in drug metabolism and chemical toxicology: An introduction. Biochem Mol Biol Educ. 34:66–74. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Guengerich FP: Cytochrome p450 and chemical toxicology. Chem Res Toxicol. 21:70–83. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Bozina N, Bradamante V and Lovric M: Genetic polymorphism of metabolic enzymes P450 (CYP) as a susceptibility factor for drug response, toxicity, and cancer risk. Arh Hig Rada Toksikol. 60:217–242. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Missmer SA, Eliassen AH, Barbieri RL and Hankinson SE: Endogenous estrogen, androgen, and progesterone concentrations and breast cancer risk among postmenopausal women. J Natl Cancer Inst. 96:1856–1865. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Chan MF, Dowsett M, Folkerd E, Bingham S, Wareham N, Luben R, Welch A and Khaw KT: Usual physical activity and endogenous sex hormones in postmenopausal women: The European prospective investigation into cancer-norfolk population study. Cancer Epidemiol Biomarkers Prev. 16:900–905. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Baglietto L, Severi G, English DR, Krishnan K, Hopper JL, Mclean C, Morris HA, Tilley WD and Giles GG: Circulating steroid hormone levels and risk of breast cancer for postmenopausal women. Cancer Epidemiol Biomarkers Prev. 19:492–502. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Rod NH, Hansen AM, Nielsen J, Schnohr P and Gronbaek M: Low-risk factor profile, estrogen levels, and breast cancer risk among postmenopausal women. Int J Cancer. 124:1935–1940. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Pearce ST and Jordan VC: The biological role of estrogen receptors alpha and beta in cancer. Crit Rev Oncol Hematol. 50:3–22. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Chen GG, Zeng Q and Tse GM: Estrogen and its receptors in cancer. Med Res Rev. 28:954–974. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Guillette TC, Jackson TW and Belcher SM: Duality of estrogen receptor β action in cancer progression. Curr Opin Pharmacol. 41:66–73. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Frech MS, Torre KM, Robinson GW and Furth PA: Loss of cyclin D1 in concert with deregulated estrogen receptor alpha expression induces DNA damage response activation and interrupts mammary gland morphogenesis. Oncogene. 27:3186–3193. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Giuliano M, Trivedi MV and Schiff R: Bidirectional Crosstalk between the estrogen receptor and human epidermal growth factor receptor 2 signaling pathways in breast cancer: Molecular basis and clinical implications. Breast Care (Basel). 8:256–262. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Levin ER: Bidirectional signaling between the estrogen receptor and the epidermal growth factor receptor. Mol Endocrinol. 17:309–317. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Sangrajrang S, Sato Y, Sakamoto H, Ohnami S, Laird NM, Khuhaprema T, Brennan P, Boffetta P and Yoshida T: Genetic polymorphisms of estrogen metabolizing enzyme and breast cancer risk in Thai women. Int J Cancer. 125:837–843. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Samavat H and Kurzer MS: Estrogen metabolism and breast cancer. Cancer Lett. 356:231–243. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Liehr JG: 4-hydroxylation of oestrogens as a marker for mammary tumours. Biochem Soc Trans. 27:318–323. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Liehr JG, Ulubelen AA and Strobel HW: Cytochrome P-450-mediated redox cycling of estrogens. J Biol Chem. 261:16865–16870. 1986. View Article : Google Scholar : PubMed/NCBI | |
|
Yager JD and Liehr JG: Molecular mechanisms of estrogen carcinogenesis. Annu Rev Pharmacol Toxicol. 36:203–232. 1996. View Article : Google Scholar : PubMed/NCBI | |
|
Cavalieri EL, Stack DE, Devanesan PD, Todorovic R, Dwivedy I, Higginbotham S, Johansson SL, Patil KD, Gross ML, Gooden JK, et al: Molecular origin of cancer: Catechol estrogen-3,4-quinones as endogenous tumor initiators. Proc Natl Acad Sci USA. 94:10937–10942. 1997. View Article : Google Scholar : PubMed/NCBI | |
|
Bradlow HL, Hershcopf RJ, Martucci CP and Fishman J: Estradiol 16 alpha-hydroxylation in the mouse correlates with mammary tumor incidence and presence of murine mammary tumor virus: A possible model for the hormonal etiology of breast cancer in humans. Proc Natl Acad Sci USA. 82:6295–6299. 1985. View Article : Google Scholar : PubMed/NCBI | |
|
Kabat GC, Chang CJ, Sparano JA, Sepkovie DW, Hu XP, Khalil A, Rosenblatt R and Bradlow HL: Urinary estrogen metabolites and breast cancer: A case-control study. Cancer Epidemiol Biomarkers Prev. 6:505–509. 1997.PubMed/NCBI | |
|
Meilahn EN, De Stavola B, Allen DS, Fentiman I, Bradlow HL, Sepkovic DW and Kuller LH: Do urinary oestrogen metabolites predict breast cancer? Guernsey III cohort follow-up. Br J Cancer. 78:1250–1255. 1998. View Article : Google Scholar : PubMed/NCBI | |
|
Lo R, Burgoon L, Macpherson L, Ahmed S and Matthews J: Estrogen receptor-dependent regulation of CYP2B6 in human breast cancer cells. Biochim Biophys Acta. 1799:469–479. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Fukasawa K, Kagaya S, Maruyama S, Kuroiwa S, Masuda K, Kameyama Y, Satoh Y, Akatsu Y, Tomura A, Nishikawa K, et al: A novel compound, NK150460, exhibits selective antitumor activity against breast cancer cell lines through activation of aryl hydrocarbon receptor. Mol Cancer Ther. 14:343–354. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Mcdaniel DO, Thurber T, Lewis-Traylor A, Berry C, Barber WH, Zhou X, Bigler S and Vance R: Differential association of cytochrome P450 3A4 genotypes with onsets of breast tumors in African American versus Caucasian patients. J Investig Med. 59:1096–1103. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Johnson N, Dudbridge F, Orr N, Gibson L, Jones ME, Schoemaker MJ, Folkerd EJ, Haynes BP, Hopper JL, Southey MC, et al: Genetic variation at CYP3A is associated with age at menarche and breast cancer risk: A case-control study. Breast Cancer Res. 16:R512014. View Article : Google Scholar : PubMed/NCBI | |
|
Johnson N, Walker K, Gibson LJ, Orr N, Folkerd E, Haynes B, Palles C, Coupland B, Schoemaker M, Jones M, et al: CYP3A variation, premenopausal estrone levels, and breast cancer risk. J Natl Cancer Inst. 104:657–669. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Mao C, Wang XW, He BF, Qiu LX, Liao RY, Luo RC and Chen Q: Lack of association between CYP17 MspA1 polymorphism and breast cancer risk: A meta-analysis of 22,090 cases and 28,498 controls. Breast Cancer Res Treat. 122:259–265. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Kuo SH, Yang SY, Lien HC, Lo C, Lin CH, Lu YS, Cheng AL, Chang KJ and Huang CS: CYP19 genetic polymorphism haplotype AASA is associated with a poor prognosis in premenopausal women with lymph node-negative, hormone receptor-positive breast cancer. Biomed Res Int. 2013:5621972013. View Article : Google Scholar : PubMed/NCBI | |
|
Sergentanis TN and Economopoulos KP: Four polymorphisms in cytochrome P450 1A1 (CYP1A1) gene and breast cancer risk: A meta-analysis. Breast Cancer Res Treat. 122:459–469. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Cardoso-Filho C, Sarian LO, de Oliveira CB, Da SBL, Lourenco GJ, Lima CS and Gurgel MS: Clinical effects of A4889G and T6235C polymorphisms in cytochrome P-450 CYP1A1 for breast cancer patients treated with tamoxifen: Implications for tumor aggressiveness and patient survival. Cancer Chemother Pharmacol. 72:529–535. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Bai X, Xie J, Sun S, Zhang X, Jiang Y and Pang D: The associations of genetic polymorphisms in CYP1A2 and CYP3A4 with clinical outcomes of breast cancer patients in northern China. Oncotarget. 8:38367–38377. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Raskin L, Lejbkowicz F, Barnett-Griness O, Dishon S, Almog R and Rennert G: BRCA1 breast cancer risk is modified by CYP19 polymorphisms in Ashkenazi Jews. Cancer Epidemiol Biomarkers Prev. 18:1617–1623. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Abraham JE, Harrington P, Driver KE, Tyrer J, Easton DF, Dunning AM and Pharoah PD: Common polymorphisms in the prostaglandin pathway genes and their association with breast cancer susceptibility and survival. Clin Cancer Res. 15:2181–2191. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Mavaddat N, Dunning AM, Ponder BA, Easton DF and Pharoah PD: Common genetic variation in candidate genes and susceptibility to subtypes of breast cancer. Cancer Epidemiol Biomarkers Prev. 18:255–259. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Justenhoven C, Hamann U, Pierl CB, Baisch C, Harth V, Rabstein S, Spickenheuer A, Pesch B, Bruning T, Winter S, et al: CYP2C19*17 is associated with decreased breast cancer risk. Breast Cancer Res Treat. 115:391–396. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Ruiter R, Bijl MJ, van Schaik RH, Berns EM, Hofman A, Coebergh JW, van Noord C, Visser LE and Stricker BH: CYP2C19*2 polymorphism is associated with increased survival in breast cancer patients using tamoxifen. Pharmacogenomics. 11:1367–1375. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Gan CQ, Wang XY, Cao YD, Ye WX, Liu H and Sun YY: Association of CYP2C19*3 gene polymorphism with breast cancer in Chinese women. Genet Mol Res. 10:3514–3519. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Yu T and Di G: Role of tumor microenvironment in triple-negative breast cancer and its prognostic significance. Chin J Cancer Res. 29:237–252. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Chen L, Joseph G, Zhang FF, Nguyen H, Jiang H, Gotlinger KH, Falck JR, Yang J, Schwartzman ML and Guo AM: 20-HETE contributes to ischemia-induced angiogenesis. Vascul Pharmacol. 83:57–65. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Garcia V, Joseph G, Shkolnik B, Ding Y, Zhang FF, Gotlinger K, Falck JR, Dakarapu R, Capdevila JH, Bernstein KE and Schwartzman ML: Angiotensin II receptor blockade or deletion of vascular endothelial ACE does not prevent vascular dysfunction and remodeling in 20-HETE-dependent hypertension. Am J Physiol Regul Integr Comp Physiol. 309:R71–R78. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Seki T, Wang MH, Miyata N and Laniado-Schwartzman M: Cytochrome P450 4A isoform inhibitory profile of N-hydroxy-N′-(4-butyl-2-methylphenyl)-formamidine (HET0016), a selective inhibitor of 20-HETE synthesis. Biol Pharm Bull. 28:1651–1654. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Garcia V, Shkolnik B, Milhau L, Falck JR and Schwartzman ML: 20-HETE activates the transcription of angiotensin-converting enzyme via nuclear Factor-κB translocation and promoter binding. J Pharmacol Exp Ther. 356:525–533. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Chen L, Ackerman R, Saleh M, Gotlinger KH, Kessler M, Mendelowitz LG, Falck JR, Arbab AS, Scicli AG, Schwartzman ML, et al: 20-HETE regulates the angiogenic functions of human endothelial progenitor cells and contributes to angiogenesis in vivo. J Pharmacol Exp Ther. 348:442–451. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Guo AM, Janic B, Sheng J, Falck JR, Roman RJ, Edwards PA, Arbab AS and Scicli AG: The cytochrome P450 4A/F-20-hydroxyeicosatetraenoic acid system: A regulator of endothelial precursor cells derived from human umbilical cord blood. J Pharmacol Exp Ther. 338:421–429. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Borin TF, Shankar A, Angara K, Rashid MH, Jain M, Iskander A, Ara R, Lebedyeva I, Korkaya H, Achyut BR and Arbab AS: HET0016 decreases lung metastasis from breast cancer in immune-competent mouse model. PLoS One. 12:e1788302017. View Article : Google Scholar : PubMed/NCBI | |
|
Borin TF, Zuccari DA, Jardim-Perassi BV, Ferreira LC, Iskander AS, Varma NR, Shankar A, Guo AM, Scicli G and Arbab AS: HET0016, a selective inhibitor of 20-HETE synthesis, decreases pro-angiogenic factors and inhibits growth of triple negative breast cancer in mice. PLoS One. 9:e1162472014. View Article : Google Scholar : PubMed/NCBI | |
|
Shankar A, Borin TF, Iskander A, Varma NR, Achyut BR, Jain M, Mikkelsen T, Guo AM, Chwang WB, Ewing JR, et al: Combination of vatalanib and a 20-HETE synthesis inhibitor results in decreased tumor growth in an animal model of human glioma. Onco Targets Ther. 9:1205–1219. 2016.PubMed/NCBI | |
|
Jain M, Gamage NH, Alsulami M, Shankar A, Achyut BR, Angara K, Rashid MH, Iskander A, Borin TF, Wenbo Z, et al: Intravenous formulation of HET0016 decreased human glioblastoma growth and implicated survival benefit in rat xenograft models. Sci Rep. 7:418092017. View Article : Google Scholar : PubMed/NCBI | |
|
Rieger MA, Ebner R, Bell DR, Kiessling A, Rohayem J, Schmitz M, Temme A, Rieber EP and Weigle B: Identification of a novel mammary-restricted cytochrome P450, CYP4Z1, with overexpression in breast carcinoma. Cancer Res. 64:2357–2364. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Yu W, Chai H, Li Y, Zhao H, Xie X, Zheng H, Wang C, Wang X, Yang G, Cai X, et al: Increased expression of CYP4Z1 promotes tumor angiogenesis and growth in human breast cancer. Toxicol Appl Pharmacol. 264:73–83. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Wang B, Zheng L, Chou J, Li C, Zhang Y, Meng X and Xi T: CYP4Z1 3′UTR represses migration of human breast cancer cells. Biochem Biophys Res Commun. 478:900–907. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Zheng L, Li X, Meng X, Chou J, Hu J, Zhang F, Zhang Z, Xing Y, Liu Y and Xi T: Competing endogenous RNA networks of CYP4Z1 and pseudogene CYP4Z2P confer tamoxifen resistance in breast cancer. Mol Cell Endocrinol. 427:133–142. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Chen P and Bonaldo P: Role of macrophage polarization in tumor angiogenesis and vessel normalization: Implications for new anticancer therapies. Int Rev Cell Mol Biol. 301:1–35. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Tariq M, Zhang J, Liang G, Ding L, He Q and Yang B: Macrophage polarization: Anti-cancer strategies to target tumor-associated macrophage in breast cancer. J Cell Biochem. 118:2484–2501. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Lao L, Fan S and Song E: Tumor associated macrophages as therapeutic targets for breast cancer. Adv Exp Med Biol. 1026:331–370. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Choi J, Gyamfi J, Jang H and Koo JS: The role of tumor-associated macrophage in breast cancer biology. Histol Histopathol. 33:133–145. 2018.PubMed/NCBI | |
|
Chen XW, Yu TJ, Zhang J, Li Y, Chen HL, Yang GF, Yu W, Liu YZ, Liu XX, Duan CF, et al: CYP4A in tumor-associated macrophages promotes pre-metastatic niche formation and metastasis. Oncogene. 36:5045–5057. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Jia X, Yu F, Wang J, Iwanowycz S, Saaoud F, Wang Y, Hu J, Wang Q and Fan D: Emodin suppresses pulmonary metastasis of breast cancer accompanied with decreased macrophage recruitment and M2 polarization in the lungs. Breast Cancer Res Treat. 148:291–302. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Ding L, Liang G, Yao Z, Zhang J, Liu R, Chen H, Zhou Y, Wu H, Yang B and He Q: Metformin prevents cancer metastasis by inhibiting M2-like polarization of tumor associated macrophages. Oncotarget. 6:36441–36455. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Lewis CE and Pollard JW: Distinct role of macrophages in different tumor microenvironments. Cancer Res. 66:605–612. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Hoopes SL, Garcia V, Edin ML, Schwartzman ML and Zeldin DC: Vascular actions of 20-HETE. Prostaglandins Other Lipid Mediat. 120:9–16. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Alexanian A and Sorokin A: Targeting 20-HETE producing enzymes in cancer-rationale, pharmacology, and clinical potential. Onco Targets Ther. 6:243–255. 2013.PubMed/NCBI | |
|
Edson KZ and Rettie AE: CYP4 enzymes as potential drug targets: Focus on enzyme multiplicity, inducers and inhibitors, and therapeutic modulation of 20-hydroxyeicosatetraenoic acid (20-HETE) synthase and fatty acid omega-hydroxylase activities. Curr Top Med Chem. 13:1429–1440. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Borin TF, Angara K, Rashid MH, Achyut BR and Arbab AS: Arachidonic acid metabolite as a novel therapeutic target in breast cancer metastasis. Int J Mol Sci. 18:26612017. View Article : Google Scholar : PubMed/NCBI | |
|
Alexanian A, Miller B, Roman RJ and Sorokin A: 20-HETE-producing enzymes are up-regulated in human cancers. Cancer Genomics Proteomics. 9:163–169. 2012.PubMed/NCBI | |
|
Zheng H, Li Y, Wang Y, Zhao H, Zhang J, Chai H, Tang T, Yue J, Guo AM and Yang J: Downregulation of COX-2 and CYP 4A signaling by isoliquiritigenin inhibits human breast cancer metastasis through preventing anoikis resistance, migration and invasion. Toxicol Appl Pharmacol. 280:10–20. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Bandala C, Floriano-Sanchez E, Cardenas-Rodriguez N, Lopez-Cruz J and Lara-Padilla E: RNA expression of cytochrome P450 in Mexican women with breast cancer. Asian Pac J Cancer Prev. 13:2647–2653. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Casos K, Siguero L, Fernandez-Figueras MT, Leon X, Sarda MP, Vila L and Camacho M: Tumor cells induce COX-2 and mPGES-1 expression in microvascular endothelial cells mainly by means of IL-1 receptor activation. Microvasc Res. 81:261–268. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Greene ER, Huang S, Serhan CN and Panigrahy D: Regulation of inflammation in cancer by eicosanoids. Prostaglandins Other Lipid Mediat. 96:27–36. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Jiang JG, Chen CL, Card JW, Yang S, Chen JX, Fu XN, Ning YG, Xiao X, Zeldin DC and Wang DW: Cytochrome P450 2J2 promotes the neoplastic phenotype of carcinoma cells and is up-regulated in human tumors. Cancer Res. 65:4707–4715. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Wei X, Zhang D, Dou X, Niu N, Huang W, Bai J and Zhang G: Elevated 14,15-epoxyeicosatrienoic acid by increasing of cytochrome P450 2C8, 2C9 and 2J2 and decreasing of soluble epoxide hydrolase associated with aggressiveness of human breast cancer. BMC Cancer. 14:8412014. View Article : Google Scholar : PubMed/NCBI | |
|
Mitra R, Guo Z, Milani M, Mesaros C, Rodriguez M, Nguyen J, Luo X, Clarke D, Lamba J, Schuetz E, et al: CYP3A4 mediates growth of estrogen receptor-positive breast cancer cells in part by inducing nuclear translocation of phospho-Stat3 through biosynthesis of (±)-14,15-epoxyeicosatrienoic acid (EET). J Biol Chem. 286:17543–17559. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Yang S, Lin L, Chen JX, Lee CR, Seubert JM, Wang Y, Wang H, Chao ZR, Tao DD, Gong JP, et al: Cytochrome P-450 epoxygenases protect endothelial cells from apoptosis induced by tumor necrosis factor-alpha via MAPK and PI3K/Akt signaling pathways. Am J Physiol Heart Circ Physiol. 293:H142–H151. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Jiang JG, Ning YG, Chen C, Ma D, Liu ZJ, Yang S, Zhou J, Xiao X, Zhang XA, Edin ML, et al: Cytochrome p450 epoxygenase promotes human cancer metastasis. Cancer Res. 67:6665–6674. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Murray GI, Patimalla S, Stewart KN, Miller ID and Heys SD: Profiling the expression of cytochrome P450 in breast cancer. Histopathology. 57:202–211. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Haas S, Pierl C, Harth V, Pesch B, Rabstein S, Bruning T, Ko Y, Hamann U, Justenhoven C, Brauch H and Fischer HP: Expression of xenobiotic and steroid hormone metabolizing enzymes in human breast carcinomas. Int J Cancer. 119:1785–1791. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Gonzalez FJ: Role of cytochromes P450 in chemical toxicity and oxidative stress: Studies with CYP2E1. Mutat Res. 569:101–110. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Vaclavikova R, Hubackova M, Stribrna-Sarmanova J, Kodet R, Mrhalova M, Novotny J, Gut I and Soucek P: RNA expression of cytochrome P450 in breast cancer patients. Anticancer Res. 27:4443–4450. 2007.PubMed/NCBI | |
|
Leung T, Rajendran R, Singh S, Garva R, Krstic-Demonacos M and Demonacos C: Cytochrome P450 2E1 (CYP2E1) regulates the response to oxidative stress and migration of breast cancer cells. Breast Cancer Res. 15:R1072013. View Article : Google Scholar : PubMed/NCBI | |
|
Cardenas-Rodriguez N, Lara-Padilla E, Bandala C, Lopez-Cruz J, Uscanga-Carmona C, Lucio-Monter PF and Floriano-Sanchez E: CYP2W1, CYP4F11 and CYP8A1 polymorphisms and interaction of CYP2W1 genotypes with risk factors in Mexican women with breast cancer. Asian Pac J Cancer Prev. 13:837–846. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Tan BS, Tiong KH, Muruhadas A, Randhawa N, Choo HL, Bradshaw TD, Stevens MF and Leong CO: CYP2S1 and CYP2W1 mediate 2-(3,4-dimethoxyphenyl)-5-fluorobenzothiazole (GW-610, NSC 721648) sensitivity in breast and colorectal cancer cells. Mol Cancer Ther. 10:1982–1992. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Moorthy B, Chu C and Carlin DJ: Polycyclic aromatic hydrocarbons: From metabolism to lung cancer. Toxicol Sci. 145:5–15. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Goth-Goldstein R, Stampfer MR, Erdmann CA and Russell M: Interindividual variation in CYP1A1 expression in breast tissue and the role of genetic polymorphism. Carcinogenesis. 21:2119–2122. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Nilsson R, Antic R, Berni A, Dallner G, Dettbarn G, Gromadzinska J, Joksic G, Lundin C, Palitti F, Prochazka G, et al: Exposure to polycyclic aromatic hydrocarbons in women from Poland, Serbia and Italy-relation between PAH metabolite excretion, DNA damage, diet and genotype (the EU DIEPHY project). Biomarkers. 18:165–173. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Al-Dhfyan A, Alhoshani A and Korashy HM: Aryl hydrocarbon receptor/cytochrome P450 1A1 pathway mediates breast cancer stem cells expansion through PTEN inhibition and beta-Catenin and Akt activation. Mol Cancer. 16:142017. View Article : Google Scholar : PubMed/NCBI | |
|
Hsu MH, Baer BR, Rettie AE and Johnson EF: The crystal structure of cytochrome P450 4B1 (CYP4B1) monooxygenase complexed with octane discloses several structural adaptations for omega-Hydroxylation. J Biol Chem. 292:5610–5621. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Mcfadyen MC, Mcleod HL, Jackson FC, Melvin WT, Doehmer J and Murray GI: Cytochrome P450 CYP1B1 protein expression: A novel mechanism of anticancer drug resistance. Biochem Pharmacol. 62:207–212. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Marsh S, Somlo G, Li X, Frankel P, King CR, Shannon WD, Mcleod HL and Synold TW: Pharmacogenetic analysis of paclitaxel transport and metabolism genes in breast cancer. Pharmacogenomics J. 7:362–365. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Bray J, Sludden J, Griffin MJ, Cole M, Verrill M, Jamieson D and Boddy AV: Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide. Br J Cancer. 102:1003–1009. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Seredina TA, Goreva OB, Talaban VO, Grishanova AY and Lyakhovich VV: Association of cytochrome P450 genetic polymorphisms with neoadjuvant chemotherapy efficacy in breast cancer patients. BMC Med Genet. 13:452012. View Article : Google Scholar : PubMed/NCBI | |
|
Schroth W, Antoniadou L, Fritz P, Schwab M, Muerdter T, Zanger UM, Simon W, Eichelbaum M and Brauch H: Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. J Clin Oncol. 25:5187–5193. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Daraei B, Aghvami M, Pourahmad J and Dinarvand R: A comparison of hepatocyte cytotoxic mechanisms for docetaxel and PLGA-docetaxel Nanoparticls. Iran J Pharm Res. 16:249–265. 2017.PubMed/NCBI | |
|
Jenkins P, Scaife J and Freeman S: Validation of a predictive model that identifies patients at high risk of developing febrile neutropaenia following chemotherapy for breast cancer. Ann Oncol. 23:1766–1771. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Hlavac V, Brynychova V, Vaclavikova R, Ehrlichova M, Vrana D, Pecha V, Trnkova M, Kodet R, Mrhalova M, Kubackova K, et al: The role of cytochromes p450 and aldo-keto reductases in prognosis of breast carcinoma patients. Medicine (Baltimore). 93:e2552014. View Article : Google Scholar : PubMed/NCBI | |
|
Nakajima M, Komagata S, Fujiki Y, Kanada Y, Ebi H, Itoh K, Mukai H, Yokoi T and Minami H: Genetic polymorphisms of CYP2B6 affect the pharmacokinetics/pharmacodynamics of cyclophosphamide in Japanese cancer patients. Pharmacogenet Genomics. 17:431–445. 2007. View Article : Google Scholar : PubMed/NCBI |
